5 Key Takeaways
-
1
Office-based therapies like selective laser trabeculoplasty (SLT) are gaining importance in glaucoma care to lower intraocular pressure (IOP).
-
2
Drs. Singh and Samuelson advocate for earlier intervention with SLT and sustained drug delivery to reduce reliance on IOP-lowering drops.
-
3
Long-term use of glaucoma drops can lead to ocular surface disease and may compromise surgical outcomes, necessitating a shift in treatment strategies.
-
4
SLT remains underutilized as a first-line therapy despite evidence supporting its safety and efficacy from the LiGHT trial.
-
5
New technologies like direct selective laser trabeculoplasty (DSLT) enhance clinic efficiency and provide noninvasive treatment options for glaucoma.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.